Ocugen eye disease gene therapy hits ph. 2 targets but underwhelms investors

Full 12-month data from Ocugen’s phase 2 eye disease gene therapy show the therapy significantly reduces the size of lesions, though the treatment’s smaller effect compared to an earlier preliminary analysis sent the biotech’s stock down a tad.